ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tedizolid phosphate

Also written as “TR-701 FA”, “Tedizolid phosphate” and “TR-701 FA 200 mg”.

Its studies are mostly in Skin Diseases, Bacterial · Bacterial Infections · Gram-Positive Bacterial Infections · Pneumonia · Skin Diseases, Infectious, led by 3 companies.

Drug pageTedizolid phosphate: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 23, 201027 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck250 open or runningphase 3since Jul 23, 2010Apr 23, 2008none ahead
Bayerits history only10 open or runningphase 3since Oct 18, 2013Oct 18, 2013none ahead
Dong-A STits history only10 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Apr 23, 2008.

  1. Sep 21, 2011Phase 1 study in Renal InsufficiencyNCT01452828 · 24 enrolled · United States
  2. Oct 26, 2011Phase 1 study in Healthy VolunteerNCT01461460 · 48 enrolled · United States
  3. Dec 19, 2011Phase 1 study in Healthy SubjectsNCT01496677 · 28 enrolled · United States
  4. Jan 24, 2012Phase 2 study in CellulitisNCT01519778 · 200 enrolled · United States
  5. Feb 21, 2012Phase 1 study in Healthy VolunteersNCT01539473 · 30 enrolled · United States
  6. Apr 11, 2012Phase 1 study in Healthy SubjectsNCT01577459 · 18 enrolled · United States
  7. Jun 6, 2012Phase 1 study in Healthy SubjectsNCT01623401 · 72 enrolled · United States
  8. Dec 18, 2013Phase 3 study in PneumoniaNCT02019420 · 726 enrolled
  9. Oct 9, 2014Phase 3 study in Skin Diseases, InfectiousNCT02276482 · 120 enrolled
  10. Jun 17, 2015Phase 1 study in Skin Diseases, BacterialNCT02477514 · 18 enrolled
  11. Apr 1, 2016Phase 1 study in Gram-Positive Bacterial InfectionsNCT02750761 · 32 enrolled
  12. Jun 1, 2017Phase 3 study in Acute Bacterial Skin and Skin Structure InfectionsNCT03176134 · 100 enrolled · United States, Brazil, Bulgaria and more
  13. Jul 12, 2017Phase 1 study in Gram-Positive InfectionsNCT03217565 · 47 enrolled · United States, Bulgaria, Colombia and more
  14. Dec 10, 2024Phase 1 study in HealthyNCT06733688 · 36 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule

Studies

All 25 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06733688Healthy · United States1CompletedApr 15, 202236
NCT03217565Gram-Positive Infections · United States, Bulgaria, Colombia and more1CompletedMar 18, 202347
NCT03176134Acute Bacterial Skin and Skin Structure Infections · United States, Brazil, Bulgaria and more3CompletedJul 6, 2023100
NCT02750761Gram-Positive Bacterial Infections1CompletedDec 16, 201832
NCT02477514Skin Diseases, Bacterial1CompletedAug 201518
NCT02276482Skin Diseases, Infectious3CompletedSep 17, 2018120
NCT02019420Pneumonia3CompletedJun 22, 2018726
NCT01623401Healthy Subjects · United States1CompletedAug 24, 201272
NCT01577459Healthy Subjects · United States1CompletedJun 15, 201218
NCT01539473Healthy Volunteers · United States1CompletedMay 201230
NCT01519778Cellulitis · United States2CompletedAug 27, 2012200
NCT01496677Healthy Subjects · United States1CompletedFeb 28, 201228
NCT01461460Healthy Volunteer · United States1CompletedDec 23, 201148
NCT01452828Renal Insufficiency · United States1CompletedMar 201224
NCT01421511Skin and Subcutaneous Tissue Bacterial Infections · United States, Argentina, Australia and more3CompletedJan 10, 2013666
NCT01431833Hepatic Impairment · United States1CompletedMay 201232
NCT01271998Bacterial Infections · United States1CompletedJan 3, 201120
NCT01170221Skin and Subcutaneous Tissue Bacterial Infections · United States, Argentina, Brazil and more3CompletedSep 30, 2011667
NCT01156077Bacterial Infections1CompletedSep 24, 201120
NCT00983255Bacterial Infections · United States1CompletedJan 201090
NCT00876655Healthy · United States1CompletedMar 200912
NCT00761215Skin Diseases, Infectious · United States2CompletedFeb 24, 2009192
NCT00671814Healthy Subjects · United States1CompletedJun 6, 200880
NCT00671359Healthy · United States1CompletedMay 15, 200812
NCT00666601Healthy · United States1CompletedAug 12, 200815

How it is read

Names in the registry

  • “TR-701 FA”, 9 entries
  • “Tedizolid phosphate”, 2 entries
  • “TR-701 FA 200 mg”, 2 entries
  • “IV Tedizolid Phosphate”, 1 entry
  • “Tedizolid Phosphate Oral Formulation 1 (Reference)”, 1 entry

Codes read as this program: TR701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.